ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: INFO24

International Registry of COVID-19 Infection in GN (IRoc-GN): Impact of COVID-19 in Patients with Glomerular Disease

Session Information

Category: Glomerular Diseases

  • No subcategory defined

Authors

  • Waldman, Meryl A., National Institutes of Health, Bethesda, Maryland, United States
  • Soler, Maria Jose, Hospital Vall d'Hebron, Barcelona, Catalunya, Spain
  • Lightstone, Liz, Imperial College London, London, London, United Kingdom
  • Griffith, Megan, Imperial College London, London, London, United Kingdom
  • Fiaccadori, Enrico, Unità Operativa Complessa di Nefrologia, Azienda Ospedaliera-Universitaria Parma, Dipartimento di Medicina e Chirurgia, Università di Parma, Parma, Italy., Parma, Italy
  • Turner-Stokes, Tabitha, Imperial College London, London, London, United Kingdom
  • García-Carro, Clara, Hospital Vall d'Hebron, Barcelona, Catalunya, Spain
  • Sinaii, Ninet, National Institutes of Health, Bethesda, Maryland, United States
  • Flossmann, Oliver, Department of Nephrology, Royal Berkshire Hospital, Reading, Berkshire, UK, Reading, United Kingdom
  • Torras, Joan, Servei Nefrologia Laboratori de Nefrologia Experimental Hospital de Bellvitge IDIBELL, Barcelona, Spain
  • Geddes, Colin C., Glasgow Renal and Transplant Unit, Queen Elizabeth University Hospital Glasgow, United Kingdom, Glasgow, United Kingdom
  • Budge, Kelly L., Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Comai, Giorgia, univ of bologna, Bologna, Italy
  • Martinez-Rueda, Armando Jezael, inst nacional de ciencias medicas, Mexico city, Mexico
  • Delsante, Marco, univ of parma, Parma, Italy
  • Cantarelli, Chiara, univ of parma, Parma, Italy
  • Cravedi, Paolo, Icahn School of Medicine at Mount Sinai, New York, New York, United States
Description

To date, there is no published data regarding the outcomes of COVID-19 in patients with underlying glomerular diseases. Though this is a heterogenous group of patients spanning a wide age range and encompassing diverse disease mechanisms, there is reason to believe that these patients may represent a particularly vulnerable group with heightened risk of severe disease manifestations due to an interplay of factors related to the immunosuppressive medications, underlying immune dysfunction, and comorbidities. To address this need for data and given the relative rarity of glomerular diseases, we created an International Registry of Covid infection in GN (I-RocGN) which was launched April 20, 2020. The registry provides a framework for collection of data on COVID-19 occurring worldwide in individuals with glomerular disease. The link to the secure public survey is https://redcapsurvey.niddk.nih.gov/surveys/?s=FPM87NK7T4 . The objective of I-RocGN is to characterize the clinical course of COVID-19, identify risk factors associated with severe complications, evaluate non-renal and renal outcomes, and assess short-term and long-term effects of COVID-19 on the underlying glomerular disease as well as relevant serologic activity. It is hoped that such data will inform strategies for prevention and treatment of COVID-19 in these patients as well provide guidance for medical management of glomerular diseases in the midst of a pandemic.

Funding

  • 1. Intramural Research Program of the NIH, The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 2. National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London